Hungary will utilize an expedited procedure to implement the cancer drug Keytruda, a well-known immunotherapy that assists the body’s own immune system in fighting cancerous cells. This decision comes after reports indicated lengthy approval times for support requests, averaging 441 days according to Direkt36. The streamlined process aims to provide faster access to this potentially life-saving treatment for patients in Hungary. Keytruda represents a significant advancement in cancer therapy through its immunotherapy approach. The previous lengthy wait times for approval posed a barrier to timely treatment. This move by Hungary seeks to overcome those obstacles and improve patient outcomes. The faster approval process will allow doctors to prescribe Keytruda more quickly to eligible patients across Hungary.